Zymeworks (ZYME) hat Anfang März 2026 einen entscheidenden Schritt zur langfristigen finanziellen Absicherung gemacht, indem das Unternehmen eine durch Lizenzgebühren…
Zymeworks sollte man als Trader jetzt auf dem Schirm haben. Es handelt sich um ein biopharmazeutisches Unternehmen, das sich auf…
…
…
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…
VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma…
VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.…
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a…
…
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of…
These are some of the stocks posting the largest moves in premarket trading.…
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the…
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
…
Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the…
…
…
Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the…
Ecor1 capital increases stake in Zymeworks with $1.88 million purchase…
VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
…
…
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms…
…
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
…
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…
…
…
…
VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…